Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

BioTrinity 2025

BioTrinity 2025 will be OBN's flagship two-day conference, taking place in its 19th year. The event will feature presentations from R&D companies at Series A [...]

OBN Science Social

OBN's Science Social event offers a fantastic opportunity for professionals in the life sciences sector to connect and build relationships in a relaxed, informal setting. [...]

OBN BioLearn: ‘Presenting with Impact’ course

This full-day, in-person course is designed to help professionals deliver high-quality, high-impact presentations with confidence and clarity. Through a mix of practical exercises and expert [...]

OBN Awards

Now in its 17th year, the OBN Awards are a prestigious and highly sought-after recognition within the life sciences sector. Designed to celebrate innovation and [...]

Go to Top